Unicycive Therapeutics (NASDAQ:UNCY) has been given a “Buy” rating by HC Wainwright

HC Wainwright reissued their buy rating on the stock Unicycive Therapeutics (NASDAQ:UNCY – Free Report) in a report published on Tuesday morning, reports Benzinga. HC Wainwright currently has a $2.50 price objective on the stock.

A number of other analysts have also recently commented on the company. Brookline Capital Management upgraded Unicycive Therapeutics to a strong-buy rating in a research report on Tuesday, July 9th. Benchmark restated a speculative-buy rating and set a $3.00 price objective on shares of Unicycive Therapeutics in a research report on Friday, May 31st. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Unicycive Therapeutics presently has a consensus rating of Buy and an average price target of $5.13, according to MarketBeat.

Read the latest stock analysis on Unicycive Therapeutics

Unicycive Therapeutics trading down 5.9%

Shares of Unicycive Therapeutics stock opened at $0.32 on Tuesday. The stock has a market cap of $30.00 million, a PE ratio of -0.27 and a beta of 2.34. The stock has a 50-day moving average price of $0.41 and a 200-day moving average price of $0.89. Unicycive Therapeutics has a 52-week low of $0.20 and a 52-week high of $1.82.

Institutional trading of unique therapy

Hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new stake in Unicycive Therapeutics in the 1st quarter worth approximately $36,000. Rosalind Advisors Inc. purchased a new stake in Unicycive Therapeutics in the 1st quarter worth approximately $2,594,000. Finally, BVF Inc. IL boosted its holdings in Unicycive Therapeutics by 70.5% in the first quarter. BVF Inc. IL now owns 3,611,601 shares of the company’s stock worth $4,984,000 after buying an additional 1,493,462 shares during the last quarter. 40.42% of shares are owned by institutional investors and hedge funds.

Unicycive Therapeutics Company Profile

(Get a free report)

Unicycive Therapeutics, Inc, a biotechnology company, is engaged in the development of new therapies for kidney disease in the United States. Renazorb is being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis; and UNI 494, which is in phase 1 clinical trials for the treatment of acute kidney injury.

Featured stories

Get news and reviews for Unicycive Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Unicycive Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.